Figure 2.
Antiproliferative effects of sorafenib-based combination treatment. A: Huh-7 and B: HEP-G2 cells were treated for 72 h with sub-IC50 concentrations of sorafenib and the histone deactylase inhibitor MS-275. Combination of both agents resulted in synergistic growth inhibition of Huh-7 cells, while rather additive growth inhibitory effects were observed in HepP-G2 cells (mean ± SEM).